London-based biotech start-up Synthace has raised £$9.7m (7.3m) in a series A funding round, featuring participation from White Cloud Capital, Amadeus Capital Partners and Eleven Two Capital, as well as existing investors. Synthace, which counts Microsoft GSK among its clients, has developed Antha, a platform enabling researchers to more easily develop biotech products and get them to market. The new funds will be used to expand Synthace's roster of biologists, suppliers, developers and cloud providers.
London-based biotech start-up Synthace has raised £7.3m ($9.7m) in a series A funding round, featuring participation from White Cloud Capital, Amadeus Capital Partners and Eleven Two Capital, as well as existing investors. Synthace, which counts Microsoft GSK among its clients, has developed Antha, a platform enabling researchers to more easily develop biotech products and get them to market. The new funds will be used to expand Synthace's roster of biologists, suppliers, developers and cloud providers.